BMJ  2005;330:1366 (11 June), doi:10.1136/bmj.330.7504.1366

Primary care

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

¹ Institution 13th floor, Tower Building, University Park, Nottingham NG2 7RD

Aims To determine the comparative risk of myocardial infarction in patients taking cyclo-oxygenase-2 and other non-steroidal anti-inflammatory drugs (NSAIDs) in primary care between 2000 and 2004; to determine these risks in patients with and without pre-existing coronary heart disease and in those taking and not taking aspirin.

Design Nested case-control study.

Setting 367 general practices contributing to the UK QRESEARCH database and spread throughout every strategic health authority and health board in England, Wales, and Scotland.

Subjects 9218 cases with a first ever diagnosis of myocardial infarction during the four year study period; 86 349 controls matched for age, calendar year, sex, and practice.

Outcome measures Unadjusted and adjusted odds ratios with 95% confidence intervals for myocardial infarction associated with rofecoxib, celecoxib, naproxen, ibuprofen, diclofenac, and other selective and non-selective NSAIDS. Odds ratios were adjusted for smoking status, comorbidity, deprivation, and use of statins, aspirin, and antidepressants.

Results A significantly increased risk of myocardial infarction was associated with current use of rofecoxib (adjusted odds ratio 1.32, 95% confidence interval 1.09 to 1.61) compared with no use within the previous three years; with current use of diclofenac (1.55, 1.39 to 1.72); and with current use of ibuprofen (1.24, 1.11 to 1.39). Increased risks were associated with the other selective NSAIDs, with naproxen, and with non-selective NSAIDs; these risks were significant at < 0.05 rather than < 0.01 for current use but significant at < 0.01 in the tests for trend. No significant interactions occurred between any of the NSAIDs and either aspirin or coronary heart disease.

Conclusion These results suggest an increased risk of myocardial infarction associated with current use of rofecoxib, diclofenac, and ibuprofen despite adjustment for many potential confounders. No evidence was found to support a reduction in risk of myocardial infarction associated with current use of naproxen. This is an observational study and may be subject to residual confounding that cannot be fully corrected for. However, enough concerns may exist to warrant a reconsideration of the cardiovascular safety of all NSAIDs.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study

Julia Hippisley-Cox, Carol Coupland, Yana Vinogradova, John Robson, Margaret May, and Peter Brindle
BMJ 2007 335: 136. [Abstract] [Full Text] [PDF]

Audit identifies the most read BMJ research papers

Susan Mayor
BMJ 2007 334: 554-555. [Extract] [Full Text] [PDF]

Life without COX 2 inhibitors: Risks and benefits are determined by dose and potency

Enrique J Sánchez-Delgado
BMJ 2006 332: 1451-1452. [Extract] [Full Text]

Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

Julia Hippisley-Cox, Carol Coupland, and Richard Logan
BMJ 2005 331: 1310-1316. [Abstract] [Full Text] [PDF]

NSAIDs may be cardiotoxic
BMJ 2005 330: 0. [Full Text]

COX 2 inhibitors, traditional NSAIDs, and the heart

Peter Jüni, Stephan Reichenbach, and Matthias Egger
BMJ 2005 330: 1342-1343. [Extract] [Full Text] [PDF]

Benefits and harms of drug treatments

Jan P Vandenbroucke
BMJ 2004 329: 2-3. [Extract] [Full Text] [PDF]

Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs

Paul Dieppe, Christopher Bartlett, Peter Davey, Lesley Doyal, and Shah Ebrahim
BMJ 2004 329: 31-34. [Extract] [Full Text] [PDF]

Efficacy and safety of COX 2 inhibitors

Roger Jones
BMJ 2002 325: 607-608. [Extract] [Full Text] [PDF]

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Peter Jüni, Anne WS Rutjes, and Paul A Dieppe
BMJ 2002 324: 1287-1288. [Extract] [Full Text] [PDF]

Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care

Julia Hippisley-Cox, Mike Pringle, Vicky Hammersley, Nicola Crown, Alison Wynn, Andy Meal, and Carol Coupland
BMJ 2001 323: 666-669. [Abstract] [Full Text] [PDF]

Magnetic resonance imaging may be alternative to necropsy

Rob Bisset
BMJ 1998 317: 1450. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Brune, K., Katus, H. A., Moecks, J., Spanuth, E., Jaffe, A. S., Giannitsis, E. (2008). N-Terminal Pro-B-Type Natriuretic Peptide Concentrations Predict the Risk of Cardiovascular Adverse Events from Antiinflammatory Drugs: A Pilot Trial. Clin. Chem. 54: 1149-1157 [Abstract] [Full text]  
• Haag, M. D. M., Bos, M. J., Hofman, A., Koudstaal, P. J., Breteler, M. M. B., Stricker, B. H. C. (2008). Cyclooxygenase Selectivity of Nonsteroidal Anti-inflammatory Drugs and Risk of Stroke. Arch Intern Med 168: 1219-1224 [Abstract] [Full text]  
• Milella, M., Metro, G., Gelibter, A., Pino, S. M., Cognetti, F., Fabi, A. (2008). COX-2 targeting in cancer: a new beginning?. Ann Oncol 19: 1209-1210 [Full text]  
• Galarraga, B., Ho, M., Youssef, H. M., Hill, A., McMahon, H., Hall, C., Ogston, S., Nuki, G., Belch, J. J. F. (2008). Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatology (Oxford) 47: 665-669 [Abstract] [Full text]  
• Hennekens, C. H., Borzak, S. (2008). Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease. J CARDIOVASC PHARMACOL THER 13: 41-50 [Abstract]  
• Sidiropoulos, P. I., Hatemi, G., Song, I.-H., Avouac, J., Collantes, E., Hamuryudan, V., Herold, M., Kvien, T. K., Mielants, H., Mendoza, J. M., Olivieri, I., Ostergaard, M., Schachna, L., Sieper, J., Boumpas, D. T., Dougados, M. (2008). Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology (Oxford) 47: 355-361 [Abstract] [Full text]  
• Hippisley-Cox, J., Vinogradova, Y., Coupland, C., Parker, C. (2007). Risk of Malignancy in Patients With Schizophrenia or Bipolar Disorder: Nested Case-Control Study. Arch Gen Psychiatry 64: 1368-1376 [Abstract] [Full text]  
• Joshi, G. P., Gertler, R., Fricker, R. (2007). Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs. Anesth. Analg. 105: 1793-1804 [Abstract] [Full text]  
• Scott, P A, Kingsley, G H, Smith, C M, Choy, E H, Scott, D L (2007). Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 66: 1296-1304 [Abstract] [Full text]  
• Timmers, L., Pasterkamp, G., de Kleijn, D. P.V. (2007). Microsomal Prostaglandin E2 Synthase: A Safer Target than Cyclooxygenases?. Mol. Interv. 7: 195-199 [Abstract] [Full text]  
• Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J., May, M., Brindle, P. (2007). Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 335: 136-136 [Abstract] [Full text]  
• Klein, T., Eltze, M., Grebe, T., Hatzelmann, A., Komhoff, M. (2007). Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Cardiovasc Res 75: 390-397 [Abstract] [Full text]  
• Waksman, J. C, Brody, A., Phillips, S. D (2007). Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe?. The Annals of Pharmacotherapy 41: 1163-1173 [Abstract] [Full text]  
• Salinas, G., Rangasetty, U. C., Uretsky, B. F., Birnbaum, Y. (2007). The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame. J CARDIOVASC PHARMACOL THER 12: 98-111 [Abstract]  
• Rostom, A., Dube, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., Moher, D. (2007). Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force. ANN INTERN MED 146: 376-389 [Abstract] [Full text]  
• Ong, C.K.S., Lirk, P., Tan, C.H., Seymour, R.A. (2007). An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs. Clin Med Res 5: 19-34 [Abstract] [Full text]  
• Rahme, E., Nedjar, H. (2007). Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 46: 435-438 [Abstract] [Full text]  
• Anning, P. B., Coles, B., Morton, J., Wang, H., Uddin, J., Morrow, J. D., Dey, S. K., Marnett, L. J., O'Donnell, V. B. (2006). Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood 108: 4059-4062 [Abstract] [Full text]  
• Mitchell, J. A., Lucas, R., Vojnovic, I., Hasan, K., Pepper, J. R., Warner, T. D. (2006). Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J. 20: 2468-2475 [Abstract] [Full text]  
• Madhok, R., Wu, O., McKellar, G., Singh, G. (2006). Non-steroidal anti-inflammatory drugs--changes in prescribing may be warranted. Rheumatology (Oxford) 45: 1458-1460 [Full text]  
• McGettigan, P., Henry, D. (2006). Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. JAMA 296: 1633-1644 [Abstract] [Full text]  
• Dalby, A. B., Frank, D. N., St. Amand, A. L., Bendele, A. M., Pace, N. R. (2006). Culture-independent analysis of indomethacin-induced alterations in the rat gastrointestinal microbiota.. Appl. Environ. Microbiol. 72: 6707-6715 [Abstract] [Full text]  
• Chaiamnuay, S., Allison, J. J., Curtis, J. R. (2006). Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.. Am J Health Syst Pharm 63: 1837-1851 [Abstract] [Full text]  
• Cheng, J. W. (2006). Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular Events. The Annals of Pharmacotherapy 40: 1785-1796 [Abstract] [Full text]  
• Fowler, P. W., Coveney, P. V. (2006). A Computational Protocol for the Integration of the Monotopic Protein Prostaglandin H2 Synthase into a Phospholipid Bilayer. Biophys. J 91: 401-410 [Abstract] [Full text]  
• Helin-Salmivaara, A., Virtanen, A., Vesalainen, R., Gronroos, J. M., Klaukka, T., Idanpaan-Heikkila, J. E., Huupponen, R. (2006). NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 27: 1657-1663 [Abstract] [Full text]  
• Gislason, G. H., Jacobsen, S., Rasmussen, J. N., Rasmussen, S., Buch, P., Friberg, J., Schramm, T. K., Abildstrom, S. Z., Kober, L., Madsen, M., Torp-Pedersen, C. (2006). Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction. Circulation 113: 2906-2913 [Abstract] [Full text]  
• Sanchez-Delgado, E. J (2006). Life without COX 2 inhibitors: Risks and benefits are determined by dose and potency.. BMJ 332: 1451-1452 [Full text]  
• Elliott, R. A., Hooper, L., Payne, K., Brown, T. J., Roberts, C., Symmons, D. (2006). Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?. Rheumatology (Oxford) 45: 606-613 [Abstract] [Full text]  
• Andersohn, F., Suissa, S., Garbe, E. (2006). Use of First- and Second-Generation Cyclooxygenase-2-Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction. Circulation 113: 1950-1957 [Abstract] [Full text]  
• Sooriakumaran, P (2006). COX-2 inhibitors and the heart: are all coxibs the same?. Postgrad. Med. J. 82: 242-245 [Abstract] [Full text]  
• Chan, A. T., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M., Curhan, G. C., Rimm, E. B., Willett, W. C., Fuchs, C. S. (2006). Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events. Circulation 113: 1578-1587 [Abstract] [Full text]  
• Harris, R. C., Breyer, M. D. (2006). Update on Cyclooxygenase-2 Inhibitors. CJASN 1: 236-245 [Abstract] [Full text]  
• Jordan, K., Porcheret, M., Kadam, U. T., Croft, P. (2006). The use of general practice consultation databases in rheumatology research. Rheumatology (Oxford) 45: 126-128 [Full text]  
• Hippisley-Cox, J., Coupland, C., Logan, R. (2005). Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331: 1310-1316 [Abstract] [Full text]  
• Hawkey, C J (2005). COX-2 chronology. Gut 54: 1509-1514 [Abstract] [Full text]  
• Conaghan, P G, Vanharanta, H, Dieppe, P A (2005). Is progressive osteoarthritis an atheromatous vascular disease?. Ann Rheum Dis 64: 1539-1541 [Abstract] [Full text]  
• Caporali, R, Montecucco, C (2005). Cardiovascular effects of coxibs. Lupus 14: 785-788 [Abstract]  
• Jones, S. F., Power, I. (2005). Editorial I: Postoperative NSAIDs and COX-2 inhibitors: cardiovascular risks and benefits. Br J Anaesth 95: 281-284 [Full text]  
• (2005). Do NSAIDs Increase Risk for MI?. Journal Watch Cardiology 2005: 7-7 [Full text]  
• Antman, E. M., DeMets, D., Loscalzo, J. (2005). Cyclooxygenase Inhibition and Cardiovascular Risk. Circulation 112: 759-770 [Full text]  
• (2005). Do NSAIDs Increase Risk for MI?. JWatch Gastroenterology 2005: 9-9 [Full text]  
• (2005). Do NSAIDs Increase Risk for MI?. JWatch General 2005: 4-4 [Full text]  

Rapid Responses:

Read all Rapid Responses

The 'pain' or the ‘drug’?

Wen Bin Liang
bmj.com, 10 Jun 2005 [Full text]

Why?

Duncan A. Peacock
bmj.com, 10 Jun 2005 [Full text]

Why do patients take NSAIDS in the first place?

Michael J Jordan
bmj.com, 10 Jun 2005 [Full text]

cause or effect ? well matching and adjusting are difficult tasks

Luca Puccetti
bmj.com, 11 Jun 2005 [Full text]

Are NSAIDs a marker for underlying inflammation and hyperviscosity?

Rupert A Gude
bmj.com, 12 Jun 2005 [Full text]

NSAID or disease - which is the risk?

Andrew N Bamji
bmj.com, 13 Jun 2005 [Full text]

Risk of Myocardial Infarction and use of Non-Steroidal Anti-Inflammatory drugs

Elliot F Epstein
bmj.com, 13 Jun 2005 [Full text]

Further anxieties and Cox inhibition

david r blake
bmj.com, 13 Jun 2005 [Full text]

Continuity of medication

M G Whitten
bmj.com, 13 Jun 2005 [Full text]

Re: Are NSAIDs a surrogate marker?

Heather A Beckett
bmj.com, 13 Jun 2005 [Full text]

NSAIDS and Heart Disease

david d holland, et al.
bmj.com, 13 Jun 2005 [Full text]

What next in pain relief?

Roger Lewis Weeks
bmj.com, 13 Jun 2005 [Full text]

Relationship to antiplatelet agents

Matt Heywood
bmj.com, 13 Jun 2005 [Full text]

Insulin is bad for you...or is it the diabetes?

John G Larkin, et al.
bmj.com, 14 Jun 2005 [Full text]

News Flash: sick people are sick

Yuval Rabinovich
bmj.com, 14 Jun 2005 [Full text]

Depressive disorders could bias the results

George Kirov
bmj.com, 14 Jun 2005 [Full text]

Study design problem?

Joseph F Standing
bmj.com, 16 Jun 2005 [Full text]

The potential dangers of a suboptimal study design

Richard Body, et al.
bmj.com, 16 Jun 2005 [Full text]

Did this study warrant the media coverage it received?

David M Pruce
bmj.com, 16 Jun 2005 [Full text]

Absolute or relative rubbish

Desmond G Julian
bmj.com, 16 Jun 2005 [Full text]

The mythology behind the scare stories

James Penston
bmj.com, 17 Jun 2005 [Full text]

Re: Did this study warrant the media coverage it received?

Stevie M Gamble
bmj.com, 17 Jun 2005 [Full text]

Is it now time to question the cardiovascular safety of all NSAIDs ?

John GF Cleland
bmj.com, 21 Jun 2005 [Full text]

Differential effects of non-steroidal anti-inflammatory drugs on the risk of myocardial infarction

Michal R. Pijak, et al.
bmj.com, 22 Jun 2005 [Full text]

Response to David Pruce

Julia Hippisley-Cox, et al.
bmj.com, 22 Jun 2005 [Full text]

Risk of myocardial infarction in patients taking some conventional NSAIDs should not be discounted but potential confounding factors ought to be better defined

Michal R. Pijak, et al.
bmj.com, 22 Jun 2005 [Full text]

Bias in cases of myocardial infarction in relation with a previous dyslipemia

Jacques M. Frey
bmj.com, 24 Jun 2005 [Full text]

Could GP consultations be the confounding variable?

Martin JB Wilkinson
bmj.com, 29 Jun 2005 [Full text]

Report from BMJ post publication review meeting

Trish Groves
bmj.com, 27 Jul 2007 [Full text]